Personalis (NASDAQ:PSNL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Personalis (NASDAQ:PSNL) from a sell rating to a hold rating in a research note released on Sunday morning.

PSNL has been the subject of several other research reports. BTIG Research increased their price objective on Personalis from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Guggenheim upped their target price on Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. Needham & Company LLC boosted their price target on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, Lake Street Capital restated a “buy” rating and set a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.57.

Personalis Price Performance

Shares of NASDAQ PSNL opened at $7.98 on Friday. The stock has a market capitalization of $708.62 million, a P/E ratio of -9.07 and a beta of 1.99. Personalis has a 1-year low of $2.83 and a 1-year high of $11.40. The business has a fifty day moving average price of $9.06 and a 200 day moving average price of $6.97.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. As a group, equities research analysts anticipate that Personalis will post -1.4 earnings per share for the current fiscal year.

Insider Transactions at Personalis

In related news, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the sale, the chief financial officer owned 164,458 shares in the company, valued at $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the transaction, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. This trade represents a 16.63% decrease in their position. The SEC filing for this sale provides additional information. 3.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Personalis

A number of hedge funds have recently modified their holdings of the stock. Aberdeen Group plc increased its position in shares of Personalis by 472.3% in the first quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock valued at $5,984,000 after buying an additional 1,406,895 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after buying an additional 1,281,695 shares during the last quarter. Geode Capital Management LLC increased its stake in Personalis by 165.6% during the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock worth $8,960,000 after acquiring an additional 851,422 shares during the last quarter. ARK Investment Management LLC raised its holdings in Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares during the period. Finally, Blue Water Life Science Advisors LP raised its stake in shares of Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock valued at $10,997,000 after acquiring an additional 500,900 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.